Premier and Bayer Diagnostics Expand Corporate Agreement

Bayer Health Care Partners and Premier Inc. announced this week that they have expanded their existing corporate agreement to include the Bayer Diagnostics Division's ADVIA 120 Hematology System.

The ADVIA 120 Hematology System features the revolutionary UniFluidics technology, offering design methodologies and cell analysis.

In addition to white cell differential analysis and RBC parameters, the ADVIA 120 Hematology System offers parameters to assist in the management of anemia through red cell and reticulocyte analysis.

The ADVIA 120 System represents the only instrument on the market, which can measure reticulocyte cellular hemoglobin assay. This is especially relevant when making differential diagnosis of anemias and in the monitoring of the responses in patients treated with recombinant human erythropoietin.

Premier represents 228 owners and more than 800 hospitals and the healthcare facilities with offices in Charlotte, NC; San Diego, CA; Westchester, IL; and Washington D.C.

Bayer's Business Group Diagnostics, headquartered in Tarrytown, NY, serves customers in 100 countries with an offering that includes diagnostics systems in three key segments: Laboratory Testing, Point of Care Testing and Self-Testing.

Bayer Health Care Partners, headquartered in Orange, CT, represents the health care business of Bayer Corporation.

Bayer Corporation, headquartered in Pittsburgh, PA is a research-based company with major businesses in health care and life sciences, chemicals and imaging technologies.